Answers are grounded in this paper and cite their sources.
Macrophages play a central role in various inflammatory diseases by regulating immune responses through the secretion of cytokines, chemokines, and growth factors, making them attractive targets for anti-inflammatory therapies. However, macrophage-modulating strategies often face challenges in the delivery specificity toward inflammatory sites, resulting in the unwanted disruption of normal immune functions. We previously identified a macrophage-targeting peptide, termed CRV. Through binding to retinoid X receptor beta (RXRΒ), CRV conjugation may navigate drugs more selectively to the inflammatory sites upon intravenous (IV) injection and thus improve their therapeutic efficacy and safety profile. Here, we optimized this CRV-guided delivery system from multiple aspects. To improve the macrophage targeting, we performed iterative molecular docking-based optimization of CRV sequence. This study identified a variant, termed CRH, with a substantially higher predicted binding affinity to RXRΒ. We further validated that compared to CRV, CRH possesses a greater affinity for RXRΒ protein and macrophage cells in vitro and exhibits a higher accumulation in inflammatory sites after IV injection in vivo. Using dexamethasone (DEX) as an example of anti-inflammatory drugs, we also investigated the impact of other components in this RXRΒ-targeted delivery system on drug biodistribution. Collectively, we report here an optimized, peptide-guided delivery system that may provide a more desirable drug biodistribution profile toward inflammatory sites and thus may serve as the foundation for a more selective delivery of anti-inflammation therapies.
No takes yet. Share an insight, caveat, or question.
Kowalke et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: